RenovoRx - רווח החברה לפני מסים, ריבית ופחת RNXT

Export control risks for high-tech software create a certain vulnerability for RenovoRx, Inc. (RNXT). The company's total operating profit on this chart demonstrates current liquidity, while 0.00 determines the current status of the parameter. Stable laboratory operations guarantee system scaling, and profitability is based on the implementation of targeted chemotherapy technologies for specialized hospitals and oncological surgeons.

This indicator measures daily operating cash flow, excluding the impact of the tax burden and debt service costs to assess the real efficiency of the business. Analyzing the EBITDA history allows an investor to correlate returns with volatility, which is critical for RenovoRx, Inc. (RNXT), as the development costs for the RenovoTAMP platform determine the company's financial stability during the clinical trial phase.